These drugs are commonly prescribed for type 2 diabetes and have gained popularity for their weight loss benefits
The starting dose is 0.6 mg daily and titrates up to a maximum daily dose of 1.8 mg daily
Eli Lilly had made early attempts to modify the fatty acid side chain of GLP-1, but did not make a mark in the field
"Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas"
[37] [38] See also [edit source] Dipeptidyl peptidase-4 Gastric inhibitory polypeptide GLP-1 receptor agonistsalbiglutide, dulaglutide, exenatide, liraglutide, lixisenatide, tirzepatide, and semaglutide, the last of which is marketed under the brands Ozempic, Rybelsus, and Wegovy
Kay Lund were postdoctoral researchers working in Joel Habener's laboratory at Massachusetts General Hospital